

January 27, 2022

BSE Limited  
P. J. Towers, Dalal Street,  
Mumbai- 400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai- 400 051

**Scrip ID-540025**

**Scrip Code-ADVENZYMES**

Dear Sir/Madam,

**Subject: Intimation of an investment proposal approved by the Board of Directors of a subsidiary, SciTech Specialities Private Limited - Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: ISIN: INE837H01020**

This is to inform that the Board of Directors of SciTech Specialities Private Limited (a 51% subsidiary), in its meeting held on January 27, 2022 has approved: (i) Investment of SciTech in Vecteng SciTech (Pty) Ltd, South Africa ("Vecteng") by acquiring / subscribing to 14% of paid up share capital of Vecteng for an amount not exceeding USD 14500 (Fourteen Thousand Five Hundred US Dollars) [i.e. approx INR 1.09 million assuming conversion rate of 1USD = INR 75 at the time of investment]; (ii) Authority to sign the Shareholder's Agreement with Vecteng.

With reference to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015, the details as intimated by SciTech in relation to the above investment of SciTech in Vectang is provided in Annexure to this letter.

Thanking you,

Yours Faithfully,  
For **Advanced Enzyme Technologies Limited**

**Sanjay Basantani**  
Company Secretary and Head – Legal

**Encl: As above**

**Annexure A**

Sr. No.	Particulars	Status / Remarks
a)	Name and address of the target entity, details in brief such as size, turnover etc.	Vecteng SciTech Pty. Ltd. Unit 1, Block A, Upper Graystone Office Park 150 Linden Street, Sandton 2196 South Africa New Start Up Entity with date of incorporation: 10 <sup>th</sup> Feb 2020 Turnover : US \$ NIL
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the acquisition/subscription of shares is not a related party transaction.
c)	Industry to which the entity being acquired belongs	Health Care
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Market expansion & growth for SciTech Specialities Pvt Ltd.'s health care products in African markets
e)	Brief details of any governmental or regulatory approvals required for the acquisition	No Govt. & Regulatory Approvals required
f)	Indicative time period for completion of the acquisition	Equity Participation to be completed by end of March 2022
g)	Nature of consideration – whether cash consideration or share swap and details of the same	14% of paid up Equity Share participation by SciTech Specialities Pvt Ltd for a consideration not exceeding US \$14,500 (cash consideration)
h)	Cost of acquisition or the price at which the shares will be acquired	Equity Shares at face value of Rand 1500 Each (i.e. approx US \$ 98 each) Authorized Equity Capital : Rand 3 Million (i.e. 2000 Equity Shares)

		Paid up Capital : Rand 1.5 Million (1000 Equity Shares) [Rand – South African Rand]
i)	Percentage of shareholding / control acquired and / or number of shares acquired	14% = 140 Equity Shares from aforesaid 1000 Equity Shares at face value of Rand 1500 per share (i.e. approx US \$ 98/share) Total purchase price of not more than US \$ 14,500
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Vecteng SciTech Pty Ltd. South Africa, is promoted by experienced professional in South Africa – Dr Pravin Semnarayan & USA-Dr (Ms.) Seema Pathak & Dr. Yashwant Pathak Date of Incorporation : 10 <sup>th</sup> Feb 2020 No Business activity during last 23 months due to pandemic. Turnover : US \$ Nil Country : South Africa

This is for your information and for public at large.

Thanking you,

Yours Faithfully,

**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**

**Company Secretary and Head – Legal**